Dendreon appoints John Osborn EVP
This article was originally published in Scrip
Dendreon Corporation has appointed John Osborn executive vice-president, general counsel and corporate secretary. Mr Osborn previously served as general counsel with US Oncology, where he worked on its recent merger with McKesson Corporation, and Cephalon, where he was responsible for all legal, government and public affairs matters.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.